Summary
Fidelity Select Pharmaceuticals is a mutual fund. It does not trade on an exchange: you buy it from the fund company at a price set once a day. Positions inside: 49. The ten largest make up 72% of the fund.
- Positions
- 49
- Dividend yield
- 4.61%
What speaks for it
- Average yearly growth over the last ten years: 7.2%.
What to watch
- The ten largest positions make up 72% of the fund, so its result rests on a few names.
- In the last five years its price once dropped by 30% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +2.6%
- 3 months
- +4.6%
- This year
- +16%
- 1 year
- +25%
- 3 years
- +58%
- 5 years
- +42%
- 10 years
- +100%
- Avg. market cap
- $397.1B
- P/E
- 27.5x
- Forward P/E
- 17.1x
- P/S
- 4.4x
- P/B
- 4.7x
- P/FCF
- 18.9x
- EV/EBITDA
- 17.9x
- Dividend yield
- 1.15%
- ROIC
- 7.5%
- ROE
- 25.8%
- Gross margin
- 69.4%
- Operating margin
- -1.4%
- Net margin
- -6.4%
- Payout ratio
- 31.7%
- Net debt/EBITDA
- 4.0x
- Beta
- 0.65
Weighted average of the 36 largest companies, which make up 93% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 LLEli Lilly LLY 24%
- 2 GSGSK GSK 7.9%
- 3 MRMerck & Co. MRK 6.4%
- 4 VTViatris VTRS 5.5%
- 5 Astrazeneca PLC (United States) 5.0%
- 6 UCUCB UCB.BR 5.0%
- 7 BMBristol-Myers Squibb BMY 4.6%
- 8 RORoche Holding AG ROP.SW 4.6%
- 9 GIGilead Sciences GILD 4.5%
- 10 ELElanco ELAN 4.3%
Positions in the fund: 49. The ten largest make up 72% of it.
Composition as of Oct 18, 2026.
Where is it spread?
By company size
- Mega cap 39%
- Large cap 48%
- Mid cap 11%
- Small cap 2.5%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M. Counted from the companies that make up 93% of the fund.
Largest size group: Large cap (48%).
What does it cost me?
We do not know the costs of this fund.
How has it done?
Growing over the long run- A year on average, 10 years
- +7.2%
- Deepest drop
- -30%
- Yearly volatility
- 22%
Average yearly growth over the last ten years: 7.2%. Deepest drop in these years: 30% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 4.61%
- Payments a year
- 2
- Last payment
- $0.78
Over the last 12 months it paid $1.68 per share, which is 4.61% of today's price. The last payment was $0.78 on Apr 10, 2026.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 27.5
- Average Bulios Score
- 56 out of 100
Weight by Bulios Fair Price
- Undervalued 18%
- Fairly valued 29%
- Overvalued 53%
On average the companies inside trade for 27.5 times their yearly profit. By Fair Price, 53% of the rated weight comes out as overvalued.
Counted from its largest companies (36), which make up 93% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Can I buy it as an ETF?
A mutual fund is bought from the fund company. These ETFs hold much of the same and trade on an exchange, so an ordinary broker carries them.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
IH IHE iShares U.S. Pharmaceuticals ETF | United States | 0.37% | $1.16B | +37% | Pays out | 51% |
PP PPH VanEck Pharmaceutical ETF | United States | 0.36% | $1.06B | +24% | Pays out | 42% |
HE HEMI Hartford Equity Premium Income ETF | United States | 0.58% | $37.0M | - | Pays out | 35% |
ME MEDX Horizon Kinetics Medical ETF | United States | 0.85% | $17.2M | +16% | Pays out | 34% |
FT FTXH First Trust Nasdaq Pharmaceuticals ETF | United States | 0.60% | $1.14B | +45% | Pays out | 32% |
IY IYH iShares U.S. Healthcare ETF | United States | 0.37% | $4.48B | +23% | Pays out | 29% |